Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Benitec Biopharma ( (BNTC) ) has issued an announcement.
Benitec Biopharma announced key executive appointments and compensation adjustments. Sophie Mukadam has been promoted to Chief Operating Officer, and Megan Boston has been appointed as Chief Financial Officer, in addition to her role as Secretary. Stock options were granted to Dr. Jerel Banks and Ms. Boston, and both executives received salary increases and adjusted target bonuses, reinforcing the company’s leadership team and aligning their incentives with company performance.
More about Benitec Biopharma
YTD Price Performance: 282.35%
Average Trading Volume: 41,136
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $286.7M
See more insights into BNTC stock on TipRanks’ Stock Analysis page.
